Page 130 - 南京医科大学学报自然科学版
P. 130

第43卷第7期
               ·1016 ·                           南 京    医 科 大 学 学         报                        2023年7月


             [7] YAO Y,ZHOU J,DIAO X,et al. Association between tu⁃  [19] LAM D C,KWOK H H,YU W C,et al. CC16 levels corre⁃
                   mor necrosis factor⁃α and chronic obstructive pulmonary  late with cigarette smoke exposure in bronchial epithelial
                   disease:a systematic review and meta⁃analysis[J]. Ther  cells and with lung function decline in smokers[J]. BMC
                   Adv Respir Dis,2019,13:1753466619866096           Pulm Med,2018,18(1):47
             [8] XIA Z,WANG Y,LIU F,et al. Association between TNF⁃  [20] BARNES P J. Oxidative stress ⁃ based therapeutics in
                   α⁃308,+489,⁃238 polymorphism,and COPD susceptibili⁃  COPD[J]. Redox Biol,2020,33:101544
                   ty:an updated Meta⁃analysis and trial sequential analysis  [21] ZENG M,LI Y,JIANG Y J,et al. Local and systemic oxi⁃
                  [J]. Front Genet,2021,12:772032                    dative stress and glucocorticoid receptor levels in chronic
             [9] HUANG H,HUANG X,ZENG K,et al. Interleukin⁃6 is      obstructive pulmonary disease patients[J]. Can Respir J,
                   a strong predictor of the frequency of COPD exacerbation  2013,20(1):35-41
                   within 1 year[J]. Int J Chron Obstruct Pulmon Dis,2021,  [22] PALIOGIANNIS P,FOIS A G,SOTGIA S,et al. Circulat⁃
                   16:2945                                           ing malondialdehyde concentrations in patients with stable
             [10] BI W,SUN Y,MA L Q,et al. Predictive role of interleukin⁃  chronic obstructive pulmonary disease:A systematic review
                   6 and CAT score in mechanical ventilation in patients  and meta⁃analysis[J]. Biomark Med,2018,12(7):771-
                   with chronic obstructive pulmonary disease at the acute  781
                   exacerbation stage in the emergency department[J].  [23] BEEH K M,BEIER J,KOPPENHOEFER N,et al. In⁃
                   World J Emerg Med,2020,11(2):93-96                creased glutathione disulfide and nitrosothiols in sputum
             [11] PRATTE K A,CURTIS J L,KECHRIS K,et al. Soluble     supernatant of patients with stable COPD[J]. Chest,
                   receptor for advanced glycation end products(sRAGE)as  2004,126(4):1116-22
                   a biomarker of COPD[J]. Respir Res,2021,22(1):127  [24] TURGUT T,ILHAN N,DEVECI F,et al. Glutathione and
             [12] POUWELS S D,KLONT F,KWIATKOWSKI M,et al.           nitrite levels in induced sputum at COPD patients and
                   Cigarette smoking acutely decreases serum levels of the  healthy smokers[J]. J Thorac Dis,2014,6(6):765-771
                   chronic obstructive pulmonary disease biomarker sRAGE  [25] MCKELVEY M C,BROWN R,RYAN S,et al. Proteases,
                  [J]. Am J Respir Crit Care Med,2018,198(11):1456-  mucus,and mucosal immunity in chronic lung disease
                   1458                                             [J]. Int J Mol Sci,2021,22(9):5018
             [13] KLONT F,HORVATOVICH P,BOWLER R P,et al.       [26] WELLS J M,PARKER M M,OSTER R A,et al. Elevated
                   Plasma sRAGE levels strongly associate with centrilobu⁃  circulating MMP⁃9 is linked to increased COPD exacerba⁃
                   lar emphysema assessed by HRCT scans[J]. Respir Res,  tion risk in SPIROMICS and COPDGene[J]. JCI Insight,
                   2022,23(1):15                                     2018,3(22):123614
             [14] BRIGHTLING C,GREENING N. Airway inflammation in  [27] UYSAL P,UZUN H. Relationship between circulating
                   COPD:progress to precision medicine[J]. Eur Respir J,  Serpina3g,matrix metalloproteinase⁃9,and tissue inhibi⁃
                   2019,54(2):1900651                                tor of metalloproteinase⁃1 and⁃2 with chronic obstructive
             [15] OBEIDAT M,LI X,BURGESS S,et al. Surfactant protein  pulmonary disease severity[J]. Biomolecules,2019,9
                   D is a causal risk factor for COPD:results of Mendelian  (2):E62
                   randomisation[J]. Eur Respir J,2017,50(5):1700657  [28] GILOWSKA I,KASPER Ł,BOGACZ K,et al. Impact of
             [16] ZIEN ALAABDEN A,MOHAMMAD Y,FAHOUM S.               matrix metalloproteinase 9 on COPD development in
                   The role of serum surfactant protein D as a biomarker of  Polish patients:genetic polymorphism,protein level,and
                   exacerbation of chronic obstructive pulmonary disease  their relationship with lung function[J]. Biomed Res Int,
                  [J]. Qatar Med J,2015,2015(2):18                   2018,2018:6417415
             [17] JOHANSSON S L,TAN Q H,HOLST R,et al. Surfactant  [29] GRÜNWALD B,SCHOEPS B,KRÜGER A. Recognizing
                   protein D is a candidate biomarker for subclinical tobacco  the molecular multifunctionality and interactome of TIMP⁃
                   smoke⁃induced lung damage[J]. Am J Physiol Lung Cell  1[J]. Trends Cell Biol,2019,29(1):6-19
                   Mol Physiol,2014,306(9):L887-L895            [30] LO C Y,HUANG H Y,HE J R,et al. Increased matrix
             [18] RONG B,FU T,GAO W,et al. Reduced serum concentra⁃  metalloproteinase⁃9 to tissue inhibitor of metalloprotein⁃
                   tion of CC16 is associated with severity of chronic obstruc⁃  ase ⁃ 1 ratio in smokers with airway hyperresponsiveness
                   tive pulmonary disease and contributes to the diagnosis  and accelerated lung function decline[J]. Int J Chron Ob⁃
                   and assessment of the disease[J]. Int J Chron Obstruct  struct Pulmon Dis,2018,13:1135-1144
                   Pulmon Dis,2020,15:461-470                                                 (下转第1021页)
   125   126   127   128   129   130   131   132   133   134   135